Drugs / AFM24
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05109442 | Nov 2021 → Mar 2025 | neoplasm | Affimed GmbH | Terminated | No outcome recorded |
| Phase 1/2 | NCT05099549 | Nov 2021 → Sep 2023 | colorectal neoplasm, head and neck squamous cell carcinoma, metastatic neoplasm, non-small cell lung carcinoma +1 | NKGen Biotech, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT04259450 | Apr 2020 → Jul 2023 | neoplastic disease or syndrome | Affimed GmbH | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AFM24 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05109442 ↗ |
| Action | Deplete | “for the specific and efficient elimination of EGFR expressing cancer cells” NCT04259450 ↗ |
| Route | Intravenous | “intravenous infusion” NCT05109442 ↗ |
| Target | EGFR | “anti-human EGFR” NCT04259450 ↗ |